Overview

Investigation on Safety, Tolerability and Pharmacokinetics of Single Doses of NNC0174-0833 in Normal Weight, Overweight to Obese But Otherwise Healthy Male Subjects

Status:
Completed
Trial end date:
2016-03-21
Target enrollment:
Participant gender:
Summary
This trial is conducted in the United States of America (USA). The aim of this trial is to investigate the safety, tolerability and pharmacokinetics of single doses of NNC0174-0833 in normal weight, overweight to obese but otherwise healthy male subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Novo Nordisk A/S